Pacira Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Pacira Biosciences, Inc. on March 22, 2023, covering events occurring on March 18, 2023. The filing addresses corporate governance changes regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
On March 18, 2023, Yvonne Greenstreet notified the Board of her intent to retire, effective March 31, 2023. Dr. Greenstreet currently serves as the Chief Executive Officer of Alnylam Pharmaceuticals, Inc. The Company is initiating a process to identify an independent Board member to replace her. The departure was not the result of any disagreement with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, or management commentary on business strategy. The primary contingency noted is the upcoming vacancy on the Board of Directors, which the Company is actively working to fill.
Key Facts for Investor Verification
- Yvonne Greenstreet will retire from the Board effective March 31, 2023.
- The resignation is voluntary and unrelated to any disputes with the Company.
- A search for a replacement independent director has been initiated.
- A press release detailing the resignation was issued on March 22, 2023 (Exhibit 99.1).